|
US2021113557A1
|
|
Methods of treating prostate cancer
|
|
WO2021077010A1
|
|
Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
|
|
WO2021067606A1
|
|
Brm targeting compounds and associated methods of use
|
|
WO2021041348A1
|
|
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
WO2021011913A1
|
|
Tau-protein targeting compounds and associated methods of use
|
|
US2020038378A1
|
|
Brm targeting compounds and associated methods of use
|
|
US2020129627A1
|
|
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
AU2019335516A1
|
|
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US2020085793A1
|
|
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
KR20210003804A
|
|
Cerebron ligand and bifunctional compound comprising the same
|
|
KR20210006356A
|
|
Proteolysis modulators and related methods of use
|
|
AU2019249849A1
|
|
BRM targeting compounds and associated methods of use
|
|
EP3710443A1
|
|
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
EP3658548A1
|
|
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3634960A1
|
|
Modulators of proteolysis and associated methods of use
|
|
WO2018144649A1
|
|
Cereblon ligands and bifunctional compounds comprising the same
|
|
AU2017382406A1
|
|
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
|
MX2019006402A
|
|
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders.
|
|
KR20200097827A
|
|
Imide-based modulators of proteolysis and associated methods of use
|
